Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial

被引：0

作者：

Ahn, M. -J. ^{[1
]}

Delmonte, A. ^{[2
]}

Ghosh, S. ^{[3
]}

Hochmair, M. ^{[4
,5
]}

Yang, T. -Y. ^{[6
]}

Yang, J. C. -H. ^{[7
,8
]}

Han, J. -Y. ^{[9
]}

Hansen, K. Holmskov ^{[10
]}

Wu, Y. ^{[11
]}

Wan, Y. ^{[11
]}

Lin, H. M. ^{[11
]}

Kretz, J. ^{[12
]}

Hupf, B. ^{[11
]}

Kurec, A. M. ^{[13
]}

Churchill, E. N. ^{[14
]}

Fram, R. J. ^{[11
]}

Cabasag, C. J. ^{[15
]}

Goriya, V. ^{[16
]}

Zhao, Y. ^{[17
]}

Gemmen, E. ^{[18
]}

Campelo, M. R. Garcia ^{[19
,20
]}

机构：

[1] Sungkyunkwan Univ, Dept Med Oncol, Samsung Med Ctr, Div Hematol,Sch Med, Seoul, South Korea

[2] IRCCS Ist Romagnolo Studio Tumori Dino Amadori I, Cesena, Italy

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria

[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[9] Natl Canc Ctr, Goyang, South Korea

[10] Odense Univ Hosp, Odense, Denmark

[11] Takeda Dev Ctr Amer Inc, Lexington, MA USA

[12] Takeda Pharmaceut Int AG, Glattpark Opfikon Zurich, Zurich, Switzerland

[13] Takeda Pharmaceut Int Singapore Emerging Markets, Singapore, Singapore

[14] Takeda Pharmaceut USA Inc, Lexington, MA USA

[15] IQVIA RDS France, Courbevoie, France

[16] IQVIA RDS France, Courbevoie, France

[17] IQVIA RDS Shanghai Co Ltd, Shanghai, Peoples R China

[18] IQVIA Falls Church, Falls Church, VA USA

[19] Univ Hosp Coruna, Dept Med Oncol, La Coruna, Spain

[20] Biomed Res Inst INIBIC A Coruna, La Coruna, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Brigatinib; ALK plus NSCLC; ALK TKI;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.12B.03

引用

页码：S200 / S200

页数：1

共 17 条

[1] Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs
Chen, Y.
Lin, H. M.
Wan, Y.
Yin, Y.
Wu, Y.
Hernandez, L.
Danes, C.
Churchill, E. N.
Dimou, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
[2] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Camidge, R.
Kim, H. R.
Ahn, M.
Yang, J. C.
Han, J.
Lee, J.
Hochmair, M.
Li, J. Y.
Chang, G.
Lee, K.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
[3] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Campelo, Maria Rosario Garcia
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander I.
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Liu, Yuyin
Vranceanu, Florin
Niu, Huifeng
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
[4] Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK plus NSCLC in ALTA-1L
Garcia-Campelo, R.
Lin, H. M.
Perol, M.
Jahanzeb, M.
Szumski, A.
Wu, Y.
Geiger, A.
Goodman, E.
Fram, R. J.
Popat, S.
Camidge, D. R.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S358 - S359
[5] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[6] Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC
Schmid, S.
Chotai, S.
Cheng, S.
Zhan, L.
Balaratnam, K.
Khan, K.
Patel, D.
Brown, M. C.
Xu, W.
Moriarty, P.
Kaidanovich-Beilin, O.
Shepherd, F. A.
Sacher, A.
Leighl, N.
Bradbury, P.
Liu, G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1088
[7] Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L)
Garcia Campelo, Maria Rosario
Lin, Huamao M.
Zhu, Yanyan
Perol, Maurice
Jahanzeb, Mohammad
Popat, Sanjay
Zhang, Pingkuan
Camidge, D. Ross
LUNG CANCER, 2021, 155 : 68 - 77
[8] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Ahn, M.
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
[9] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Camidge, D. Ross
Tiseo, Marcello
Ahn, Myung-Ju
Reckamp, Karen
Hansen, Karin
Kim, Sang-We
Huber, Rudolf
West, Howard
Groen, Harry
Hochmair, Maximilian
Leighl, Natasha
Gettinger, Scott
Langer, Corey
Paz-Ares, Luis
Smit, Egbert
Kim, Edward
Reichmann, William
Clackson, Tim
Kerstein, David
Haluska, Frank
Kim, Dong-Wan
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
[10] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
Gettinger, Scott N.
Bazhenova, Lyudmila
Salgia, Ravi
Langer, Corey J.
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice
Weiss, Glen J.
Dorer, David J.
Rivera, Victor M.
Conlan, Maureen G.
Kerstein, David
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239

← 1 2 →